Health Professional Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Professional Times.

Press releases published on April 17, 2026

Apr. 17, 2026

WuXi AppTec's CRDMO Model: Integrating Research, Development, and Manufacturing into a Unified Platform

Indeterminate EIN Presswire

Apr. 17, 2026

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Indeterminate GlobeNewswire

Apr. 17, 2026

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Indeterminate GlobeNewswire

Apr. 17, 2026

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details

Indeterminate GlobeNewswire

Apr. 17, 2026

Brazilian Wood Claims Evaluated: Discover the Male Enhancement Hardening Pill Truth by SuperNatural Man

Indeterminate GlobeNewswire

Apr. 17, 2026

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Indeterminate GlobeNewswire

Apr. 17, 2026

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Indeterminate GlobeNewswire

Apr. 17, 2026

Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Indeterminate GlobeNewswire

Apr. 17, 2026

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

Indeterminate GlobeNewswire

Apr. 17, 2026

JimStoppani.com Announces Summer Shred Challenge with $25,000 Grand Prize

Indeterminate GlobeNewswire

Apr. 17, 2026

Can You Trust AI Therapy? New Report Exposes the Potential Risks of General AI for Mental Health

Indeterminate EIN Presswire

Apr. 17, 2026

How Top Injection Mold Label Manufacturers Are Reshaping Packaging Standards Worldwide

Indeterminate EIN Presswire

Apr. 17, 2026

Opticore Eye Group Unveils New Contact Lens Program in Riverside, CA for 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

From 18 Months to 90 Days: Pulse Convert Fast-Tracks the Journey to Microsoft Fabric for Global Enterprises,90% Accuracy

Indeterminate EIN Presswire

Apr. 17, 2026

Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity

Indeterminate GlobeNewswire

Apr. 17, 2026

JellyLean Claims Evaluated: Discover the Untold Truth About Jelly Lean Gelatin Trick Gummies Recipe for Weight Loss

Indeterminate GlobeNewswire